EVMN Stock Analysis: Buy, Sell, or Hold?
$14.02
0.45 (3.32%)
â˛
5d:
-4.3%
30d:
+23.85%
90d:
-40.47%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When EVMN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EVMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EVMN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVMN is currently trading at $14.02, which is considered slightly high relative to its 30-day fair value range of $11.48 to $14.11.
Technical Outlook: Technically, EVMN is in a strong downtrend. Immediate support is located at $13.20, while resistance sits at $15.06. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: EVMN scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.57 (+96.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVMN is in a strong downtrend. Immediate support is located at $13.20, while resistance sits at $15.06. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: EVMN scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.57 (+96.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$11.48 -
$14.11
Company Quality Score
40/100
(HOLD)
Options IV Signal
47th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
52.1%
All Signals
- NEUTRAL: Options fairly priced (IV 47th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 96.7% below Wall St target ($27.57)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.48 -
$14.11
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$2.09
(14.9%)
Support & Resistance Levels
Support Level
$13.20
Resistance Level
$15.06
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$27.57
(+96.7%)
Share & Embed Analysis
Last updated: August 24, 2026 2:50 AM ET
Data refreshes hourly during market hours. Next update: 3:50 AM
Data refreshes hourly during market hours. Next update: 3:50 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVMN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |